Contineum Therapeutics Inc (NASDAQ: CTNM) kicked off on Friday, down -8.82% from the previous trading day, before settling in for the closing price of $3.91. Over the past 52 weeks, CTNM has traded in a range of $3.42-$22.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -50.00%. While this was happening, its average annual earnings per share was recorded -11.62%. With a float of $13.50 million, this company’s outstanding shares have now reached $19.14 million.
Let’s determine the extent of company efficiency that accounts for 41 employees. In terms of profitability, gross margin is -24.79%, operating margin of -24410.74%, and the pretax margin is -20591.32%.
Contineum Therapeutics Inc (CTNM) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Contineum Therapeutics Inc is 47.82%, while institutional ownership is 43.21%. The most recent insider transaction that took place on Nov 25 ’24, was worth 16,177. In this transaction Chief Scientific Officer of this company sold 1,010 shares at a rate of $16.02, taking the stock ownership to the 168,562 shares. Before that another transaction happened on Nov 18 ’24, when Company’s Chief Scientific Officer sold 6,190 for $16.38, making the entire transaction worth $101,421. This insider now owns 169,572 shares in total.
Contineum Therapeutics Inc (CTNM) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -11.62% per share during the next fiscal year.
Contineum Therapeutics Inc (NASDAQ: CTNM) Trading Performance Indicators
Take a look at Contineum Therapeutics Inc’s (CTNM) current performance indicators. Last quarter, stock had a quick ratio of 21.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.93, a number that is poised to hit -0.45 in the next quarter and is forecasted to reach -3.01 in one year’s time.
Technical Analysis of Contineum Therapeutics Inc (CTNM)
Looking closely at Contineum Therapeutics Inc (NASDAQ: CTNM), its last 5-days average volume was 0.14 million, which is a jump from its year-to-date volume of 74460.0. As of the previous 9 days, the stock’s Stochastic %D was 34.99%. Additionally, its Average True Range was 0.47.
During the past 100 days, Contineum Therapeutics Inc’s (CTNM) raw stochastic average was set at 1.18%, which indicates a significant decrease from 13.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 128.23% in the past 14 days, which was higher than the 80.62% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.11, while its 200-day Moving Average is $12.11. However, in the short run, Contineum Therapeutics Inc’s stock first resistance to watch stands at $3.77. Second resistance stands at $3.98. The third major resistance level sits at $4.12. If the price goes on to break the first support level at $3.43, it is likely to go to the next support level at $3.30. Now, if the price goes above the second support level, the third support stands at $3.09.
Contineum Therapeutics Inc (NASDAQ: CTNM) Key Stats
The company with the Market Capitalisation of 92.23 million has total of 25,872K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -42,260 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -15,990 K.
